<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301677</url>
  </required_header>
  <id_info>
    <org_study_id>XPM-033</org_study_id>
    <nct_id>NCT01301677</nct_id>
  </id_info>
  <brief_title>Ultra Violet B Radiation (UVR) Study of Strontium Chloride Hexahydrate Hydrocortisone</brief_title>
  <official_title>Double-blind, Randomised, Active (Hydrocortisone) Controlled Study of the Effect of 10% w/v Strontium Chloride Hexahydrate on Ultraviolet B Radiation (UVR) Induced Signs of Inflammation (Erythema and Pain) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>X-pert Med GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>X-pert Med GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blinded (subject and observer), randomised, active (hydrocortisone (HC)) controlled&#xD;
      study of the effect of strontium chloride hexahydrate on ultraviolet B radiation (UVR)&#xD;
      induced signs of inflammation (erythema and pain) in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects that signed the informed consent and are eligible to the study will be irradiated on&#xD;
      the back to evaluate their individual minimal erythema dose (MED).&#xD;
&#xD;
      A training session (without study medication) will be performed in order to introduce&#xD;
      subjects to the testing and rating procedures.&#xD;
&#xD;
      Subjects will come in within 28 days of screening to start the treatment period of the study.&#xD;
&#xD;
      For eligible subjects, three test areas oriented along the long axis of the back and&#xD;
      different from the areas of MED determination will be defined for the evaluation of effects&#xD;
      on pain and inflammation induced by UVR. The three areas will be irradiated with 2 MED. In&#xD;
      addition, non-irradiated, not treated areas will serve as reference and training areas for&#xD;
      the individual visits.&#xD;
&#xD;
      Topical treatments will be randomly assigned to the three test areas.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of erythema</measure>
    <time_frame>at 6 h, 12 h, 24 h, 36 h, 48 h post UVR</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain threshold (primary hyperalgesia to heat)</measure>
    <time_frame>Sum of assessments at 6 h, 12 h, 24 h, 36 h, 48 h post UVR</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">47</enrollment>
  <condition>Erythema</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2PX+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>strontium chloride hexahydrate in a penetration enhancing vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2PX-</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>strontium chloride hexahydrate without a penetration enhancing vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone liquid formulation</description>
    <arm_group_label>Hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2PX+</intervention_name>
    <description>strontium chloride hexahydrate in a penetration enhancing vehicle</description>
    <arm_group_label>2PX+</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2PX-</intervention_name>
    <description>strontium chloride hexahydrate without a penetration enhancing vehicle</description>
    <arm_group_label>2PX-</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent prior to any study-mandated procedure&#xD;
&#xD;
          -  Subjects in good health as determined by the Investigator&#xD;
&#xD;
          -  Willing and able to comply with study requirements&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Fitzpatrick skin types I, II, or III&#xD;
&#xD;
          -  Willing to avoid sun exposure, tanning lamps and use of any topical products on the&#xD;
             test areas during the study&#xD;
&#xD;
          -  Willing not to wash test areas during treatment period&#xD;
&#xD;
          -  Willing to abstain from sauna, exposure to extreme cold or major physical activities&#xD;
             during the treatment period of the study&#xD;
&#xD;
          -  For females, subjects of childbearing potential (including peri-menopausal women who&#xD;
             have had a menstrual period within 1 year) must be using appropriate birth control&#xD;
             (defined as a method which results in a low failure rate, i.e., less than 1% per year&#xD;
             when used consistently and correctly, such as implants, injectables, some intrauterine&#xD;
             contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner). Oral&#xD;
             contraceptive medications are allowed in this study. Female subjects, who are&#xD;
             surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)&#xD;
             are also allowed for participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  Planned treatment or treatment with another investigational drug within 30 days prior&#xD;
             to randomization.&#xD;
&#xD;
          -  Subjects who are inmates of psychiatric wards, prisons, or other state institutions&#xD;
&#xD;
          -  Investigator or any other team member involved directly or indirectly in the conduct&#xD;
             of the clinical study&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Any known factor or disease that might interfere with treatment compliance, study&#xD;
             conduct or interpretation of the results such as drug or alcohol dependence or&#xD;
             psychiatric disease.&#xD;
&#xD;
        Medical History&#xD;
&#xD;
          -  Malignancy within the past 2 years with the exception of in situ removal of basal cell&#xD;
             carcinoma&#xD;
&#xD;
          -  Known hypersensitivity or allergy (including photoallergy) to hydrocortisone,&#xD;
             strontium chloride hexahydrate, glycofurol, dimethylsulphoxide (DMSO), ethanol,&#xD;
             propylene glycol, glycerol, hypomellose, sodium edentate, sodium hydroxide, citric&#xD;
             acid monohydrate and metagin&#xD;
&#xD;
          -  History of photosensitivity disease&#xD;
&#xD;
          -  Sunburn, excessive tan, uneven skin tones or blemishes of the test areas&#xD;
&#xD;
          -  Pain conditions which might interfere with pain rating during the study, e.g.&#xD;
             neuropathic pain&#xD;
&#xD;
          -  Open wounds, infection, inflammation or other dermal diseases of the intended&#xD;
             application areas&#xD;
&#xD;
          -  ALT or AST ≥ 5 times the ULN&#xD;
&#xD;
          -  Glomerulary filtration rate &lt; 30 ml/min&#xD;
&#xD;
        Medication History&#xD;
&#xD;
          -  Systemic or topical drugs that might affect responses to UVR or interfere with&#xD;
             responses to IMP including corticosteroids, thiazides, tetracyclines and NSAIDs must&#xD;
             be washed out with 5 times half-life time prior to randomization to treatment&#xD;
&#xD;
          -  Drugs with potential dermatologic adverse events defined by the respective summary of&#xD;
             product characteristics (e.g. tetracyclines, gyrase inhibitors) must be washed out&#xD;
             with 5 times half-life time prior to randomization to treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilka Rother, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>X-pert Med GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>X-pert Med GmbH</name>
      <address>
        <city>Graefelfing</city>
        <state>Bavaria</state>
        <zip>82166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>X-pert Med Gmbh</name>
      <address>
        <city>Jena</city>
        <state>Thuringia</state>
        <zip>07745</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>February 17, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>June 28, 2011</last_update_submitted>
  <last_update_submitted_qc>June 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ilka Rother, MD</name_title>
    <organization>X-pert Med GmbH</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

